Bionomics : Statutory Accounts - Form 6-K -September 29, 2023 at 10:53 am EDT

Statutory Accounts





Director's Report


In accordance with the Corporations Act 2001, the directors of...

Related Keywords

United States ,Canada ,Australia ,London ,City Of ,United Kingdom ,City Of London ,Thorney ,Peterborough ,Adelaide ,South Australia ,Australian ,Spyridon Papapetropoulos ,Kadrian Hinton ,Ndas Blas ,La Monte Carlo ,David Wilson ,Alan Fisher ,Connor Bernstein ,Merck Sharpe Dohme ,Neurocrine Biosciences ,Spyros Papapetropoulos ,Alan Fisher Bcom ,Dupont Merck ,Jane Ryan ,Nigel Stevenson ,Liz Doolin ,Cs Pharmaceuticals ,Lundbeck ,Rejuveron Life Sciences ,Group Leadership Team ,Neurocrine Biosciences Inc ,Research Collaboration ,Pfizer Inc ,Group Treasury ,Research Development ,Therapeutic Inc ,Allen Overy ,Movement In Net Deferred Tax Liability ,Remuneration Committee Of The Board ,Development Incentive ,Group As Lessor ,Apeiron Investments Group Ltd ,Subsidiaries Of Bionomics ,Nasdaq ,Bionomics Limited Is Ernst Young ,Neurocrine Biosciences Bionomics Limited Ipos ,Lipocine Inc ,Development Incentives ,Synaptic Pharmaceuticals ,Group As Lessee ,Teva Pharmaceuticals Inc ,Carina Biotech Pty Ltd ,Adamas Pharmaceuticals Inc ,Risk Management Committee ,Ernst Young ,Rothschild Co ,International Financial Reporting Standards ,International Financial Reporting Board ,Biogen Inc ,Neuropore Therapies Inc ,For Committee Member ,Archemix Corp ,Interactive Strength Inc ,Apeiron Investment Group ,Capital Markets Solutions ,Australia Limited ,Group Is Bionomics ,Allergan ,Drug Administration ,Biodel Inc ,Credit Suisse Group ,Loan Movement Schedule ,Risk Committee Meetings ,Nikon Corporation ,Bionomics Limited Or Company ,Bionomics Limited ,Risk Committee Of Thorney Technologies Limited ,Bionomics Inc ,Anatara Lifesciences Ltd ,Ironwood Pharmaceuticals Inc ,International Accounting Standards Board ,Centrepoint Alliance Limited ,Vigil Neuroscience Inc ,Governance Institute Of Australia ,Audit Services ,Forward Foreign Exchange ,National Institutes Of Health ,Bionomics Limited The Company ,Catalyst Biosciences Inc ,Head Of Small Companies Corporate Broking ,Bionomics Company ,Iliad Chemicals Pty ,Services Tax ,Cavion Inc ,Catalyst Bosciences Inc ,Piper Jaffray Ltd ,Ernst Young Global ,Details Of The Group ,Directors Of The Company ,Wg Partners ,Government Research ,Therapeutics Inc ,Directors Of Bionomics ,Movements In Ordinary Shares Of The Company ,Synaptic Pharmaceutical Corp ,Queensland University ,Remuneration Committee ,Statutory Accounts ,Corporations Act ,Non Executive Director ,Non Executive Chairman ,Errol De Souza ,Executive Chairman ,Aaron Weaver ,Miles Davies ,Chief Executive Officer ,Executive Director ,Operating Results ,Contingent Value Rights ,Channel Expertise ,Drive Growth ,Pipeline Expansion ,Continued Development ,Depression Rating Scale ,Insomnia Severity Index ,Sheehan Disability Scale ,Large Market ,Significant Unmet Need ,Ongoing Collaboration ,Merck Sharpe ,License Agreement ,Legacy Oncology Assets ,Carina Biotech ,Expected Results ,Options Granted ,Employee Equity Plan ,Share Option Plan ,Risk Committee ,Thorney Technologies Limited ,Listed Directorships ,Last Three Years ,National Institutes ,Cyclerion Therapeutics ,Royalty Pharma ,Catalyst Biosciences ,Palatin Technologies ,Previously Mr Wilson ,Global Chairman ,Group Leadership ,Joint Head ,United Kingdom Investment Banking Group ,Deutsche Bank ,Small Companies Corporate Finance ,Small Companies Corporate ,Senior Independent Director ,Suisse Group ,Chartered Financial Analyst ,Interactive Strength ,Managing Director ,Enterprise Value ,Chief Medical Officer ,Chief Development Officer ,Clinical Development ,Acadia Pharmaceuticals Inc ,Swanbio Therapeutics ,Before Cavion ,Teva Pharmaceuticals ,Pharmaceuticals Inc ,Chief Executive ,Bionomics Company Secretary ,Governance Institute ,Corporate Secretariat ,Corporate Governance ,Company Secretary ,Committee Member ,William Street ,Young Global ,Professional Standards Legislation ,Annual Report ,Comprehensive Income ,Income Tax ,Comprehensive Loss ,Consolidated Statement ,Financial Position ,Cash Flows ,Operating Activities ,Investing Activities ,Financing Activities ,Cash Equivalents ,Financial Statements ,Accounting Standards ,Australian Accounting Standards Board ,Australian Accounting Standards ,Revised Accounting Standards ,Income Taxe ,Employee Benefits ,Share Based Payment ,Non Current Assets Held ,Discontinued Operation ,Contingent Liabilities ,Contingent Asset ,Long Term Employee ,Bionomics Employee Equity Plan ,Annual General Meeting ,General Meeting ,Consultancy Agreement ,Employee Share Option Plan ,Financial Assets ,Effective Interest Method ,Indefinite Lived Intangibles ,Deferred Tax ,Assets Acquired ,Eclipse Therapeutic ,Continuing Operations ,Australian Government ,Income Tax Recognised ,Accounting Loss ,Net Deferred Tax Liability Recognised ,Net Deferred Tax Liability ,Net Deferred Tax Asset Not Recognised ,Tax Consolidation ,Carrying Amounts ,Ordinary Shares ,Bionomics Employee Share Option Plan ,Offer Date ,Offer Date The ,Monte Carlo ,Currency Translation Reserve ,Payments Reserve ,Financial Instruments ,Risk Management ,Treasury Policy ,Chief Financial Officer ,Interest Rate Risk ,Financial Reports ,Operating Loss ,Net Cash Outflow ,Operating Assets ,Per Share ,Average Number ,New Chief Executive Officer ,Options Issued ,Financial Statement ,Equipment Commitments ,Eclipse Therapeutics ,Ironwood Pharmaceuticals ,Corporations Regulations ,Australian Auditing ,Accounting Professional ,Ethical Standards Board ,Professional Accountants ,Independence Standards ,Australian Auditing Standards ,Markets ,